Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes.
A number of protease inhibitors (PIs) are dependent on an acidic gastric pH for optimal drug dissolution and absorption. As a result, the potential for negative drug interactions with acid-reducing agents exists and could lead to subtnerapeutic drug concentrations, viral breakthrough, and development of drug resistance. Pharmacokinetic evaluations of a number of PIs given with acid-reducing agents have been performed and show varying degrees of effect. Given the possibility of decreases in PI exposures, clinicians should be aware of the potential for a negative interaction when selecting PI-based HAART for patients taking acid-reducing agents.
Luber
Andrew D
AD
University of Pennsylvania, Philadelphia, USA.
D000143:Acids; D000069446:Atazanavir Sulfate; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D009842:Oligopeptides / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D016896:Treatment Outcome
D000143:Acids; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate